Company intelligence / Profile preview

Zocentive

Albuquerque, New Mexico, United Statescn.linkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Zocere developed an injectable neuroprotectant peptide drug licensed from University of New Mexico technology, targeting acute neurological injuries such as stroke and concussion. No published clinical results are available; development status after initial preclinical work remains unclear[5].

Therapeutic areas: Neurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

TAT-STEP

Preclinical

Partnerships

University of New Mexico/STC.UNM (licensing partner for STEP peptide technology)[5]

Beyond the preview

Go deeper on Zocentive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zocentive.

Explore the full profile